Biopsy-based predictors of prostate cancer mortality: The Mayo Model Feb. 21, 2014 Overview Show transcript Overview Matthew K. Tollefson, M.D., a urologic oncologist at Mayo Clinic's campus in Rochester, Minnesota, in his article appearing in the March 2014 issue of Mayo Clinic Proceedings, using the Mayo Model, provides patients and clinicians with a novel way to predict which cases of prostate cancer, the most commonly diagnosed malignancy in American men, will be aggressive and which ones can be safely monitored with watchful waiting. Receive Mayo Clinic news in your inbox. Sign up Related ContentArticleTherapeutic sequencing improves outcomes for patients with progressive mCRPC Q and AHigh-intensity focused ultrasound for the treatment of prostate cancer VID-20440019 Medical Professionals Biopsy-Based Predictors of Prostate Cancer Mortality: The Mayo Model